MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical ...
Stock market today: Wall Street ticks higher ahead of the Fed’s decision on interest rates
U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...
McKesson’s Strong Q2 Performance Leads to Upward EPS Revision, But Hold Rating Due to Segment Concerns and Uncertain Long-Term Growth
Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...
Wall Street Climbs on Earnings and Fed Rate Cut Expectations
The Dow Jones Industrial Average fell 62 points, or 0.1 percent, while the Nasdaq composite rose 0.7 percent. McKesson, a ...
McKesson's Fiscal Q2 EPS Tops Forecast
McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per ...
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
McKesson Corporation Reports Strong Q2 Earnings Growth
McKesson Corporation ( (MCK) ) has released its Q2 earnings. Here is a breakdown of the information McKesson Corporation presented to its ...
McKesson upgraded at Baird on Core Ventures deal after Q2 beat
McKesson (MCK) stock traded higher as Baird upgraded the company to outperform citing its Core Ventures deal and its strong Q2 FY25 earnings. Read more here.
kalkinemedia7h
Baird Sees McKesson Stock Poised for Upside, Driven by US Pharma...
Highlights:,Baird upgraded McKesson Corporation’s stock from Neutral to Outperform, raising its price target to $688 from $531.,McKesson's strong performance in the U.S. Pharmaceutical Distribution ...
What you need to know in Baltimore’s opioid case before it heads to jurors
Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...